clinical trial · NCT07335601
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
MASH - Metabolic Dysfunction-Associated SteatohepatitisResmetiromPlacebo
brief summary
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
started
Dec 29, 2025
primary completion
Jul 1, 2027
completion
Dec 1, 2027
last updated
Apr 30, 2026
official title
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol